Patient Empowerment World Congress Europe

Patient Empowerment World Congress 2025 Europe

Part of the Patient Centricity & Collaboration Series

“The importance of Patient Empowerment in pharma and healthcare in achieving improved health outcomes, building greater trust, and driving innovation within the industry"

00Days
00Hours
00Minutes
00Seconds

Book now Apply To Speak

Exhibit & sponsorship opportunities

Patient meets Innovation & Collaboration

Patient empowerment and understanding to inspire and create a meaningful impact.

Introduction
Insight
Who Should Attend

FACILITATE LIVE is very pleased to welcome you to our upcoming PATIENT EMPOWERMENT World Congress 2025 Europe. The congress focuses on “The importance of Patient Empowerment
in pharma and healthcare in achieving improved health outcomes, building greater trust, and driving innovation within the industry”.

Involving patients in their treatment decisions and ensuring their understanding of care plans greatly enhances adherence to prescribed medications and therapies. This approach, integrating shared decision-making with comprehensive patient education, enables individuals to make informed choices, leading to improved health outcomes. The advantages of patient empowerment are extensive, including quicker recovery times, reduced anxiety, and an increased likelihood of patients proactively managing their health through healthier lifestyle choices and effective condition monitoring.

When patients feel heard and respected, it strengthens their bond with healthcare providers, fostering more open communication and better collaboration. Engaging with patients and demonstrating a commitment to their needs builds trust and cultivates positive perceptions of the pharmaceutical industry. Patient empowerment necessitates transparency in research, development, and treatment information, achievable through clear communication and accessible resources. Patient input is invaluable for driving innovation and efficiency in healthcare, as it helps identify unmet needs, design more effective clinical trials, and develop new therapies that are truly relevant to patients’ lives. When patients are actively involved in the research process, they are more likely to participate in clinical trials and remain engaged throughout the study.

By understanding patient preferences and experiences, pharmaceutical companies can develop more personalized and effective treatments and support programs. Furthermore, empowered patients can provide valuable feedback on patient support programs, aiding in their refinement and improvement. Patient empowerment aligns with ethical principles that respect individual autonomy, enabling patients to make informed decisions about their health. By ensuring all patients have access to the necessary information and support, patient empowerment can help address health disparities and promote health equity. Ultimately, patient empowerment is a key driver in moving towards a healthcare system where patients are active participants and their needs are at the center of care.

The two-day Congress aims to foster significant conversations and collaborations among various key stakeholders, including those in the healthcare and pharma industries, advocacy groups, clinicians, researchers, and, most importantly, patients and their caregivers.

We will focus on patient empowerment and its implications for both patients and the pharmaceutical and life science industries. I hope this event will spark insightful discussions.

We look forward to meeting you at the Congress!

Sincerely yours,

Jocelyn Raguindin
Conference Director
Paradigm Global Events / Facilitate Live

GAIN LATEST INSIGHTS ON:

Collaborative decision-making measures to ensure patients, pharma and healthcare providers work together to make informed treatment decisions, recognizing patients as equal partners.
Providing clear and accessible information to patients about their conditions, treatments, and available options to empower their active participation.
Patient involvement in treatment decisions and understanding of care plans improves adherence to medication and therapies.
Fostering more open communication and better collaboration with healthcare providers ensuring they feel heard and understood.
Patient input is crucial for healthcare innovation to help identify unmet needs, design better clinical trials, and develop more relevant therapies.
Actively engaging patients in the research process to increase participation, better trial outcomes, and a more patient-centred research environment.
Pharmaceutical companies can develop more personalized and effective treatments and support programs by understanding patient preferences and experiences,
Shifting approach from a paternalistic model to a collaborative approach that places patients at the center of their healthcare journey.
Strategies to encourage healthcare professionals to develop the skills and attitudes necessary for adapting to the evolving role of patients.
Addressing health disparities and promote health equity by ensuring all patients have access to the necessary information and support
Role of researchers in bridging the communication gap between life science industry and the patient it serves
How to achieve a deeper understanding of the patient experience in the real world

WHO SHOULD ATTEND?

This Congress is beneficial to patients, pharmaceutical, biotech companies, researchers, physicians, patient advocacy groups, regulatory agencies, technology, and healthcare companies.

Network with Presidents, Heads/Chiefs, VPs, Directors, and Managers in the area of:

Patients
Patient Engagement
Patient Centricity
Patient Empowerment
Head of Patient Engagement
Patient Services
Engagement Strategy
R&D Patient Engagement
Medical Affairs
Regulatory Affairs and Policy
Patient Support and Patient Engagement
RWE, and Data Management
Quality and Compliance
Clinical Development
Programme Management
Supply Chain Management
Patient Access
Clinical Research
Global Head, Digital Accelerator
Patient Engagement & Portfolio Strategy
Patient Support Strategy & Insights
Patient Experience

Medical Affairs, Global Patient Advocacy & Alliances
Government Policy and Advocacy
Digital Patient Experience Lead
Clinical Operations
Clinical Insights and Experience
Head of Strategy, Access Services
Vice President, Site Collaborations and Patient Centricity
Head of Neuroscience
And much more...

00Days
00Hours
00Minutes
00Seconds

Key Industry Expert Speakers 2025

Comfirmed speakers Apply to speak

Schedule

Content Rich Program Agenda! Featuring Keynote Presentations, Stream Sessions, Panel, and Round Table Discussions.

Day 1 25/09/2025
Day 2 26/09/2025

08:00 am - WELCOME COFFEE & REGISTRATION

08:30 am - CHAIRPERSON’S OPENING REMARKS

Anthony Cunliffe, National Lead Medical Adviser, Macmillan Cancer Support

KEY ASPECTS OF PATIENT EMPOWERMENT

8:40 am - OPENING KEYNOTE PANEL: Explore the significance of patient empowerment within the pharmaceutical and life science industries?

Challenges in achieving healthcare equity and how these barriers relate to the rise of consumer-driven healthcare models
Identifying the necessary actions for hospitals and policymakers to ensure individuals can afford essential diagnostic tests and treatments without delaying care.
How stakeholders in the healthcare system can cultivate an environment that empowers patients to better understand the cost and quality of the treatments they receive?
How healthcare organizations are adapting to the increasing involvement of patients in their own healthcare and how this shift has influenced their strategies and product development.

Moderator:

Victoria Hayes, Director Public Affairs, Kyowa Kirin

Panelists:

Geoff Rollason, Formerly Patient Experience and Service Lead at Pfizer UK

Daniel Newman, Patient Advocate, Diabetes UK’s Science and Research Advisory Group

Emily Reuben OBE, CEO & Co-founder, Duchenne UK

Ankita Batla, Senior Vice President, Medical Strategy, Klick Health

9:20 am - SETTING THE SCENE: What is Patient Empowerment?

Standard definition
Patient perspective
Other suggestions and open discussions

Carole Scrafton, Director & Co-Founder, Flutters and Strutters

9:50 am - PLENARY KEYNOTE: Importance of partnerships between the pharmaceutical industry and patient/patient organizations for improving health outcomes

Areas of focus for patient advocacy partnerships
Best practice in working together to produce better outcomes for patients
Benefits of working together
Embracing a patient-centric mindset and keep the patient front of mind
How to interact in every way with the groups that represent those patients

Wafae Iraqi, Patient Engagement Lead, EMEA, Johnson & Johnson

10:20 am - MORNING NETWORKING REFRESHMENTS

11:00 am - PLENARY KEYNOTE: Moving forward with patients and public

The importance of patient perspectives in regulatory processes
The benefits of prioritising patients’ needs and preferences in drug- and device-related decisions
The value of understanding public and patient acceptability of risk and benefits
Influencing medical product developers to involve patients in their development pathway

Lawrence Tallon, Chief Executive Officer, M H R A

11:30 am - SPONSORED SPOTLIGHT: Leveraging key components of an effective patient engagement strategy

Enhancing provider schedules and empowering patients to book their appointments, thereby boosting accessibility and satisfaction.
Applying technological solutions to improve the coordination of care.
Optimizing processes to decrease inefficiencies, delays, and revenue shortfalls.
Encouraging patient involvement through portals, applications, and educational materials.

RESERVED

12:00 pm - SPONSORED SPOTLIGHT: Healthcare in the Era of AI: Ethical Considerations, Challenges, and Future Trends.

Introduction and historical context
AI’s current applications in healthcare
Legal and ethical considerations
Challenges to AI integration
Future trends in AI implementation within healthcare.

RESERVED

12:30 pm - PLENARY SESSION: Goodbye patient perspective. Hello patient expert

How one parent led charity changed the paradigm for research, access and care in Duchenne Muscular Dystrophy
Hercules – an award winning collaboration putting patient expertise at the heart of developing tools for HTA Duchenne UK created a global partnership with pharma and academics to give companies the best chance possible of successful HTA submissions
DMD Hub – how the patient desire for clinical trials drove a £4million investment in clinical trial infrastructure in the UK
DMD Care – how Duchenne UK created a national collaboration between patients and clinicians to improve SoC across the board.

Emily Reuben OBE, CEO & Co-founder, Duchenne UK

1:00 pm - NETWORKING LUNCH

KEY ASPECTS OF PATIENT EMPOWERMENT

2:00 pm - SESSION CHAIR OPENING REMARKS

2:10 pm - It Takes Two to Tango - Evolving dynamics in 21st Century Healthcare

Patient empowerment – a partner dance on a crowded dancefloor
Mapping the steps – what does the evidence say?
Stepping on toes – where the dance falters
Choreographing next steps

Dr Liz Clark, Visiting Lecturer & Patient Engagement Theme Lead, King’s College London

2:40 pm - Second best is not good enough: supporting patients with inflammatory conditions in their pursuit of remission

Elevate remission as a meaningful and achievable treatment goal
Highlight civil society perspectives on the burden of inflammatory conditions and the need for remission- focused care
Identify key policy and health system barriers to pursuing remission
Develop patient advocacy strategies to address these barriers

Neil Betteridge, Patient Advocate, Sr Director, Europe,
GAfPA

3:10 pm - Patient engagement in healthcare - fact or fiction?

My experience in healthcare delivery
The view from pharma
How does it feel for patients?

Geoff Rolasson, Formerly Patient Experience and Service Lead at Pfizer UK

3:40 pm - AFTERNOON NETWORKING REFRESHMENTS

4:20 pm - My Journey of Living with a Rare Disease, Disability, and Now Advocacy

Living with Osteogenesis Imperfecta and navigating life across two healthcare systems – Germany & the UK
My experiences as a disabled student in mainstream education, and the importance of inclusive support
The emotional and mental health impact of living with a rare condition, and confronting stigma head-on
Speaking at the House of Lords, the Department for Work and Pensions, and the World Health Assembly
Why patient voices—especially from disabled and rare disease communities must shape policies and systems

Niveda Kiridaran, Youth Advocate, Rare Diseases Int’l
Youth Leadership Programme

4:50 pm - Breast Cancer Now’s Service Pledge – evolving our approach to maximise impact for patients and NHS services

Facilitating partnership working between patients and healthcare professionals
Evolving our approach to meet the changing needs in the NHS
Breaking down barriers to engagement – successes and learnings
The challenge of reach vs need
Maximising the impact for patients through supporting hospital staff

Catherine Wood, Head, Healthcare Prof. Support &
Engagement, Breast Cancer Now

CLINICAL RESEARCH & TECHNOLOGY

2:00 pm - SESSION CHAIR OPENING REMARKS

Anthony Cunliffe, National Lead Medical Adviser,
Macmillan Cancer Support

2:10 pm - Is 'patient centricity' resulting in people empowerment?

What does patient centricity actually mean?
How is it applied in the clinical and research worlds?
What’s the difference between engaging with feedback from people in the research world compared to the clinical world?
Are we doing enough?

Amelia Hursey, Strategic Director, parkinsonseurope.org

2:40 pm - JOINT PRESENTATION: The Human Element: How Smart Technology Fosters Authentic Partnerships in Clinical Trials – Moving Beyond Transactional Interactions

How can technology truly empower authentic patient partnerships in clinical research?
We will explore how to strategically deploy ever advancing technology where it directly addresses a specific patient or research challenge.
We will also address the need to shift the ‘us versus
them’ mindset

Keith Berelowitz, Founder/CEO, pRxEngage Inc
Thomas Smith, Patient expert living with Cystic
Fibrosis, pRxEngage Inc

3:10 pm - Cross-border access to paediatric clinical trials: lessons learned

Language accommodation in the conduction of cross- border clinical trials
Children’s rights in the access to science
Analysis of the state of the art: Europe as attractive ecosystem for cross-border access to clinical research
Patient involvement in the design of cross-borders studies.

Begoña Nafría Escalera, Coordinator of eYPAGnet, Hospital
Sant Joan de Déu

3:40 pm - AFTERNOON NETWORKING REFRESHMENTS

4:20 pm - Supporting the Storytellers: Educating and Sustaining Lived Experience Leaders

Best practices for training and supporting lived experience educators in healthcare.
Empowering patients and families as co-educators and leaders—not just participants.
Embedding authentic patient partnership into clinical education and peer support.
Supporting patients through the emotional impact of storytelling and advocacy.
Creating space for patient-led innovation to improve care and connection.

Monica Hulsey, Family as Faculty, Patient & Caregiver
Educator, Holland Bloorview Kids Rehabilitation
Hospital

4:50 pm - Amplifying lived expertise through the development of Target Product Profiles

The value and power of foresight at the earliest possible stage of product development
Identifying and maintaining relevance to the target patient population
Supporting mechanisms for optimal efficacy and adherence

Lorna Allen, Senior Involvement Manager, Cystic Fibrosis
Trust

5:20 pm - PANEL DISCUSSION: A critical need for a holistic approach to patient empowerment

Breaking down silos for comprehensive strategy to anticipate challenges and opportunities in both short and long term
Addressing urgent policy changes and stakeholder concerns while planning for the future
Integrating patient-centricity into the broader patient access strategy
Harmonisation imperative for sustained growth

Moderator:

Panellist:

Glenn Darley, Patients Engagement Lead EMEA, Recordati Rare Diseases

Beverly Lui, former Head, Patient Advocacy and Engagement International Region, Apellis

Lopa Ghosh, Sr Advisor, Policy & Communications, Global Health Advocacy Incubator

6:15 - 7:15 pm - NETWORKING DRINK RECEPTION

8:00 am - WELCOME COFFEE & REGISTRATION

8:30 am - CHAIRPERSON’S OPENING REMARKS

Emma Sutcliffe, Founder, ISPEP

CHALLENGES & OPPORTUNITIES IN EMPOWERING PATIENTS

8:40 am - KEYNOTE PANEL: Diversity, equality, and inclusion (DEI) practices in healthcare to ensure all patients receive high-quality care tailored to their individual needs

How can DEI empower individuals
Promoting cultural competency, understanding the social determinants of health that affect specific
communities and considering patients’ unique needs
How DEI improves patient outcomes thru better communication, build trust and address systemic biases?
Evidence-based interventions to tackle disparities in health status and access to care
Benefits of integrating patient engagement with diversity, equity, and inclusion in new medical product development

Moderator:

Panellists:

Steve Clark, Founder and Patient Advocate, Strive for Five

Lara Bloom, President and CEO, The Ehlers-Danlos Society

Sarah Cross Ph, Vice President, Global Head of Medical Affairs, Premier Research

9:20 am - PLENARY KEYNOTE: Humanising Clinical Conversations: How Healthcare Professionals Talk to Patients?

Explore the transformative power of empathy and communication in clinical settings.
Emphasize the need to shift from transactional medical dialogue to person-centred conversations.
Challenge systemic norms that dehumanize the patient experience.

Lara Bloom, President and CEO, The Ehlers-Danlos Society

9:50 am - PLENARY KEYNOTE: Why Patients and People with Lived Experience Should Want to Act to Implement the WHA Social Participation Resolution

This resolution is not just symbolic. It provides a concrete, evidence-backed roadmap for engaging patients, people with lived experience, healthcare providers, and civil society in a structured, measurable, accountable and resourced way in health system design, delivery and decision-making. It is an opportunity to reshift focus on the health outcomes that matter –too often health is done to people, not with people. And it’s an opportunity for the patient community to claim its space once and for all.

Amanda Bok, Chief Partnership Officer, The Synergist

10:20 am - MORNING NETWORKING REFRESHMENTS

11:00 am - PLENARY SESSION: Effective clinical communication crucial for patient empowerment within the healthcare system.

How clinical communication facilitates empowerment?
Benefits of effective communication
Barriers to effective communication
Examples of empowering communication strategies

Steve Clark, Founder and Patient Advocate, Strive for Five

11:30 am - PLENARY SESSION: Unheard: Experiences of Women diagnosed with gynaecological cancer.

This topic will cover the work that we have done as a charity to raise the profile of experiences of women being diagnosed with gynae cancer and
How using patient voices influence change within the NHS

Lowri Griffiths, Director of Support, Policy & Insight, Tenovus Cancer Care

12:00 pm - SPONSORED SPOTLIGHT: Embedding patient perspectives into day-to-day activities and decisions

(This session has been fully funded and developed by Novo Nordisk)

The importance of a patient engagement strategy
Why embedding patient engagement principles across a whole organisation is essential
How will the pharmaceutical industry know if it is truly patient centric

Catherine Brant, Advocacy and Engagement Lead, Novo Nordisk UK

12:30 pm - SPONSORED SPOTLIGHT: Healthcare in the Era of AI: Ethical Considerations, Challenges, and Future Trends.

Introduction and historical context
AI’s current applications in healthcare
Legal and ethical considerations
Challenges to AI integration
Future trends in AI implementation within healthcare.

RESERVED

1:00 pm - NETWORKING LUNCH

COLLABORATION & SHARED DECISION-MAKING

AFTERNOON CHAIRPERSON:

Jennifer Costello, Executive Director, Global Patient Outreach (GPO), Bristol Myers Squibb

2:00 pm - PLENARY SESSION: The Value of Patient Collaboration in the Real World: Case Studies from Burden of Disease to Adherence

The purpose of this presentation is to showcase the significant impacts of patient involvement in various Real-World Evidence (RWE) studies conducted at Servier. By engaging different patient advisory boards, we have enhanced our protocol designs, gained a deeper understanding of the burden of disease for patients with severe conditions, and identified barriers to better adherence, ultimately improving the continuum of care. research within the pharmaceutical industry setting

Delphine Nicolas, Director, Patient Engagement & Advocacy, Servier Pharmaceuticals

2:30 pm - PLENARY SESSION: How to Leverage behavioral science methods to improve patient’s ENGAGEMENT in clinical trials

Why behavior in the real-world matters
Barriers to diverse participation are multifactorial
How to support enrollment in clinical trials for patients benefit

Sylvie Coumel, Global Behavioral Science Lead, Sanofi

3:00 pm - PLENARY SESSION: Drive Community Health Equity by Uniting National and Local Collaborations

This session explores collaboration with leading national patient advocacy organizations on health equity work in collaboration with community based organizations.

Understand work with the ADA in Birmingham, highlighting collaborative efforts to address patient access issues from screening to specialty care.
Explore the initiatives undertaken with NMSS to tackle neurology desert areas, ensuring access to quality care and support for individuals affected by Multiple Sclerosis.
Learn about the collaborative work with ACS to advance cancer health equity, aiming to reduce disparities in cancer prevention, treatment, policy and support services.

Sonali Chopra, Executive Director, Patient Advocacy Relations, GENENTECH

3:30 pm - AFTERNOON NETWORKING REFRESHMENT

4:00 pm - Stronger Together, #morethanahashtag

To follow shortly

Lindsay Randall, Founder, CEO, Mother, Arthur’s Quest / SLC6A1 Connect UK

4:30 pm - CLOSING PANEL DISCUSSION: Adopting a multidisciplinary approach that addresses the full spectrum of patient needs, beyond just medical care

Fundamental aspects of patient advocacy, including its definition and core concepts
How advocacy serves as a vital link between patients and healthcare providers
Practical strategies for effective patient advocacy
Real-world case studies and exploring emerging trends shaping the future of patient advocacy

Moderator:

Emma Sutcliffe, Founder, ISPEP

Panelists:

Delphine Nicolas, Director, Patient Engagement & Advocacy, Servier Pharmaceuticals

Beverly Lui, Head, Patient Advocacy and Engagement International Region, Apellis

Lopa Ghosh, Senior Advisor, Policy & Communications, Global Health Advocacy Incubator

Geoff Rollason, Patient Advocate, former Patient Experience and Service Lead, Pfizer UK
Jennifer Costello, Executive Director, Global Patient Outreach (GPO), Bristol Myers Squibb

5:10 pm - CHAIRPERSONS CLOSING REMARKS

Emma Sutcliffe, Founder, ISPEP

Jennifer Costello, Executive Director, Global Patient Outreach (GPO), Bristol Myers Squib

Event Partners

Sponsors & Exhibitors - Patient Empowerment World Congress 2025 Europe

Disclaimer: Novo Nordisk [and other sponsoring companies] have provided sponsorship funding to Facilitate Live to support the delivery of this conference. Novo Nordisk [and other sponsoring companies] have had no editorial input or influence over the agenda, content development or choice of speakers, except for sponsored spotlight presentations when indicated.

Become a sponsor/exhibitor

Newsletter Sign Up

No Spam – You will only receive relevant information on Patient Centricity & Collaboration, and event updates

Testimonials

what people say

Thank you for a good experience with the PARADIGM Global Events… very high level, very good Organization, we overpassed our expectatives, we will be pending for another congress related to pharmaceutical and biotech… we learned a lot, and i think that the content of agenda was state of the art, thank you again.

Salvador Berrios

ERP/ CRM / Product Configurator Manager

The consistently high quality of international faculty was most impressive. It was also obvious that they were carefully chosen not only for their particular expertise but also for their ability to communicate the subject matter to clinical and non-clinical participants alike. As market access consultant for pharma clients of various sizes, I now feel much better prepared to explain the nuances & dynamics involved in bringing their products to market. In addition, I am in a much better position to intelligently advice my clients & help them set realistic expectations

Thomas Martin

Associate Vice President, VCGA - Quintiles

I was impressed with the organization of this event. I attend many conferences per year and find the organizers on site to be detached and not focus on good service to the delegates. This team was even providing weather forecast warning to ensure everyone was aware and made appropriate plans. Well Done.